earnings digest health biogen idec inc biogen idec inc s fourth quarter profit nearly doubled on growing sales of treatments for cancer and multiple sclerosis but shares fell as investors shrugged off the results and the positive outlook the company offered for tysabri a new multiple sclerosis drug pulled from the market two years ago over safety questions shares of biogen idec were down &# at &# in p m nasdaq stock market composite trading the cambridge mass biotechnology company said a rise in revenue was led by a increase in sales of rituxan a treatment for non hodgkins lymphoma and rheumatoid arthritis that the company co promotes in the u s with genentech inc sales of biogen idecs top selling drug an year old ms treatment called avonex rose to &# million though sales growth has recently leveled off 
